Needham Reiterates Buy on Theseus Pharmaceuticals, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia reiterates a Buy rating on Theseus Pharmaceuticals (NASDAQ:THRX) and maintains a $23 price target.
May 26, 2023 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Theseus Pharmaceuticals and maintains a $23 price target.
The news directly mentions Theseus Pharmaceuticals (THRX) and the analyst's Buy rating and price target of $23. This reaffirmation of the Buy rating by Needham analyst Ami Fadia could positively impact the stock price in the short term as it signals confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100